Innovation has been central to America’s economic success since the nation’s founding. In a new column for RealClearMarkets, Market Institute President Charles Sauer argues that policymakers should remember the vital role patents have played in driving growth, investment, and technological advancement. Sauer traces the history of patents from the earliest Read more…
Market Institute President Charles Sauer joined the Scott Sloan Show on 700 WLW to discuss the need for Medicare Advantage reform as policymakers focus on reducing waste, fraud, and abuse in federal healthcare programs. During the conversation, Sauer explained how Medicare Advantage provides valuable choices for seniors but also contains Read more…
Market Institute President Charles Sauer warns in a new Washington Examiner op-ed that proposals to impose Section 232 tariffs on medical devices would ultimately increase healthcare costs for Americans while doing little to strengthen an industry the United States already leads. As the Trump administration considers whether to expand tariffs Read more…
Listen Here Market Institute President Charles Sauer joined Lars Larson on “The Lars Larson Show” to discuss why Alzheimer’s policy could become a defining issue in the upcoming election cycle — especially in key swing states. The conversation focused on new polling data, early diagnosis, access to treatment, and the Read more…
A new op-ed by Charles Sauer in the Washington Times argues that earlier Alzheimer’s diagnosis is not only a healthcare issue, but also a financial one for millions of American families. In the piece, Sauer explains how cognitive decline often begins affecting financial decision-making years before a formal diagnosis, leaving Read more…
In a recent piece for the Daily Caller, Charles Sauer highlights a growing disconnect between medical innovation and public policy when it comes to Alzheimer’s care—and the consequences could not be more serious. Health and Human Services Secretary Robert F. Kennedy Jr. recently put it plainly: “it is regulatory malpractice Read more…
The House Energy and Commerce Committee’s Subcommittee on Health recently held a hearing examining the drivers of rising health care costs. While much of the discussion focused on consolidation among providers, a key cause of that consolidation received far less attention: the Section 340B drug pricing program. As Charles Sauer Read more…
Healthcare is intensely personal, especially when devastating diagnoses arrive. Yet too often, a system weighed down by regulation and bureaucracy compounds that pain, forcing patients and families to navigate life-altering decisions without the support or flexibility they need. In a recent piece published on The Capitalist Substack, Market Institute President Read more…
In a recent column for RealClearMarkets, Market Institute Senior Fellow Norm Singleton examines how a well-intentioned federal program has morphed into a major source of wasteful healthcare spending and industry consolidation. Total healthcare spending is projected to reach nearly $6 trillion this year, with more than $2 trillion coming from Read more…
In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation. Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Read more…